Stockscreener 앱 받기
6.14
1.92%
-0.12
전일 마감가:
$6.26
열려 있는:
$6.3
하루 거래량:
422.95K
Relative Volume:
0.74
시가총액:
$199.68M
수익:
-
순이익/손실:
$-29.25M
주가수익비율:
-5.1771
EPS:
-1.186
순현금흐름:
$-22.80M
1주 성능:
-1.13%
1개월 성능:
+1.49%
6개월 성능:
-35.77%
1년 성능:
+43.79%
1일 변동 폭
$6.12
$6.3618
1주일 범위
$5.975
$6.42
52주 변동 폭
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
명칭
Sagimet Biosciences Inc
전화
(650) 561-8600
주소
155 BOVET RD., SUITE 303, SAN MATEO
SGMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.14 | 203.59M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 개시 | Wedbush | Outperform |
| 2025-08-07 | 재개 | H.C. Wainwright | Buy |
| 2025-07-24 | 개시 | Canaccord Genuity | Buy |
| 2024-12-06 | 개시 | Oppenheimer | Outperform |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-06-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-05-02 | 개시 | H.C. Wainwright | Buy |
| 2024-03-25 | 개시 | Leerink Partners | Outperform |
| 2023-08-08 | 개시 | Goldman | Buy |
| 2023-08-08 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-08 | 개시 | Piper Sandler | Overweight |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
모두보기
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5%Here's Why - MarketBeat
Trend Review: Can Sagimet Biosciences Inc deliver alphaWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Will Sagimet Biosciences Inc stock keep outperforming rivalsJuly 2025 WrapUp & Fast Entry High Yield Tips - Bộ Nội Vụ
Death Cross: Can Sagimet Biosciences Inc stock reach 100 price targetPortfolio Risk Summary & High Return Trade Opportunity Guides - Bộ Nội Vụ
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target - TipRanks
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - Улправда
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally - RTTNews
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 Fed Impact & Verified Short-Term Plans - Улправда
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - Улправда
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - Улправда
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - Улправда
Published on: 2026-01-08 19:16:00 - Улправда
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewswire
Study links experimental drug to improved liver fibrosis in MASH patients - Stock Titan
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
Why Sagimet Biosciences Inc. stock could rally in 2025Gap Up & Verified Entry Point Detection - Улправда
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4%Still a Buy? - MarketBeat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha
Can Sagimet Biosciences Inc. stock maintain growth trajectoryJuly 2025 Levels & Daily Entry Point Trade Alerts - DonanımHaber
Sagimet reports positive Phase 1 results for MASH combination therapy By Investing.com - Investing.com Australia
How Sagimet Biosciences Inc. stock performs in high volatility marketsPrice Action & Low Volatility Stock Suggestions - DonanımHaber
Guidance Update: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
How Sagimet Biosciences Inc. (0O2) stock compares with top peersWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
Investment Review: Why Sagimet Biosciences Inc. stock could be next big winnerMarket Sentiment Review & Fast Exit and Entry Trade Guides - Улправда
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress - TipRanks
Sagimet reports positive Phase 1 results for MASH combination therapy - Investing.com India
Sagimet Biosciences Announces Positive Phase 1 PK Trial Results - TradingView — Track All Markets
[8-K] Sagimet Biosciences Inc. Reports Material Event | SGMT SEC FilingForm 8-K - Stock Titan
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - The Manila Times
Sagimet Biosciences Announces Positive Results from the - GlobeNewswire
Sagimet Biosciences (Nasdaq:SGMT) Secures Global License for Resmetirom API in Combination Program - Kalkine Media
Sagimet Biosciences enters global license agreement with TAPI - MSN
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences Signs License Agreement With Teva Subsidiary for Resmetirom Development - marketscreener.com
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development - GuruFocus
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - The Manila Times
Sagimet Biosciences Inc Enters License Agreement with TAPI - TradingView — Track All Markets
Sagimet Biosciences (NASDAQ: SGMT) signs TAPI deal for resmetirom API combo - Stock Titan
Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire
Sagimet Biosciences Earnings Notes - Trefis
What the Technical Setup Suggests for HCKK Ventures Limited in the Next 30 Days - earlytimes.in
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - MSN
Sagimet Biosciences Inc (SGMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):